Equities research analysts forecast that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will report $0.05 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Pacira Pharmaceuticals’ earnings. The highest EPS estimate is $0.10 and the lowest is $0.02. Pacira Pharmaceuticals posted earnings per share of ($0.11) during the same quarter last year, which would suggest a positive year-over-year growth rate of 145.5%. The business is expected to announce its next earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that Pacira Pharmaceuticals will report full-year earnings of $0.25 per share for the current year, with EPS estimates ranging from $0.12 to $0.43. For the next year, analysts expect that the company will post earnings of $0.96 per share, with EPS estimates ranging from ($0.36) to $2.19. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Pacira Pharmaceuticals.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, May 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. Pacira Pharmaceuticals had a negative net margin of 11.45% and a negative return on equity of 5.81%. The company had revenue of $74.61 million for the quarter, compared to analyst estimates of $73.92 million. During the same period in the prior year, the business earned ($0.19) earnings per share. Pacira Pharmaceuticals’s quarterly revenue was up 7.7% on a year-over-year basis.
A number of brokerages have recently issued reports on PCRX. JPMorgan Chase & Co. upped their target price on shares of Pacira Pharmaceuticals from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 10th. Canaccord Genuity set a $34.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, May 11th. ValuEngine upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 9th. HC Wainwright reiterated a “buy” rating and set a $48.00 target price (up from $45.00) on shares of Pacira Pharmaceuticals in a research report on Monday, April 9th. Finally, BMO Capital Markets reduced their target price on shares of Pacira Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $45.00.
In related news, insider Richard Scranton sold 1,367 shares of the business’s stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $33.02, for a total transaction of $45,138.34. Following the completion of the sale, the insider now directly owns 12,226 shares of the company’s stock, valued at $403,702.52. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO David M. Stack sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $33.79, for a total transaction of $844,750.00. Following the sale, the chief executive officer now directly owns 115,446 shares of the company’s stock, valued at $3,900,920.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 49,093 shares of company stock valued at $1,700,983. 5.90% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. HealthCor Management L.P. increased its stake in Pacira Pharmaceuticals by 8.6% in the fourth quarter. HealthCor Management L.P. now owns 2,800,000 shares of the company’s stock valued at $127,820,000 after purchasing an additional 221,960 shares in the last quarter. Armistice Capital LLC increased its stake in Pacira Pharmaceuticals by 13.9% in the fourth quarter. Armistice Capital LLC now owns 328,000 shares of the company’s stock valued at $14,973,000 after purchasing an additional 40,000 shares in the last quarter. State of Wisconsin Investment Board increased its stake in Pacira Pharmaceuticals by 35.9% in the fourth quarter. State of Wisconsin Investment Board now owns 39,400 shares of the company’s stock valued at $1,799,000 after purchasing an additional 10,400 shares in the last quarter. Macquarie Group Ltd. increased its stake in Pacira Pharmaceuticals by 9.7% in the fourth quarter. Macquarie Group Ltd. now owns 1,266,414 shares of the company’s stock valued at $57,812,000 after purchasing an additional 111,869 shares in the last quarter. Finally, Redmile Group LLC bought a new stake in Pacira Pharmaceuticals in the fourth quarter valued at approximately $237,000.
Shares of Pacira Pharmaceuticals traded down $0.50, reaching $33.75, during trading hours on Friday, MarketBeat reports. 1,152,148 shares of the company were exchanged, compared to its average volume of 675,686. Pacira Pharmaceuticals has a fifty-two week low of $26.95 and a fifty-two week high of $51.10. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -58.19 and a beta of 1.77. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 1.00.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.